With the rapid increase in interest from international markets for the drug and medical device industries in the Indian market, the various bodies governing healthcare are aiming to tighten regulations with an interest on patient safety. Pertaining on the issue of storage temperature on medicine labels, the Indian Pharmaceuticals Association (IPA) wants the Drug Controller General of India (DCGI) to formalize some guidelines. During a cross country study, the IPA found that most of the products do not have proper labeling and some surprisingly don’t even have the label for storage instructions. To solve this non-uniformity with the labels, the IPA has strictly said it should be made mandatory to have labels of minimum storage temperature and medical products without such labels must be terminated from the Indian market.
The DCGI is controlled by the Drugs and Cosmetics Act of 1945. Medical devices were largely unregulated since its inception. Since 2009, medical device regulations have been separated from pharmaceutical regulations. Clearly defined labeling requirements for medical devices were formulated in 2014 and constant updates based on panels such as IPA, medical device advisory boards are being made.
The IPA also insists a clear-cut temperature specification as current labeling doesn’t specify proper temperature as it reads ‘room temperature’, ‘store in cool place’ which is very confusing and ineffective as different parts of the country will have different climates. The general secretary of the IPA, Kaushik Desai said: “There is should be clear mention to room temperature which should include range of both upper and lower temperature to avoid all the non-needed statements in the label which confuses the people.
He added “The guidelines for the storage temperature labels should be structured on a priority considering the risks involved. The steps for implementing the proposed GDP by DTAB should also be taken by the CDSCO immediately.”
Other News
Imports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read MoreErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read MoreTUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read MoreTGA Supports MHRA’s New Regulations
The TGA made a commitment to support the MHRA‘s new Regulations worldwide recognition framework for pharmaceuticals. Following the UK’s exit from the European Union, a new international recognition framework for medicines has been developed specifically […]
Read More